Fresenius (NYSE:FMS) business group Fresenius Kabi said today that its Dilaudid hydromorphone HCl injection is available in 4 different presentations of the Simplest prefilled syringes.

The Lake Zurich-Ill. company’s Simplist syringes have a 2-year shelf life and do not require any assembly or point-of care preparation.

The prefilled syringes sport different colors associated with different dose strengths and are clearly labelled to avoid confusion between hydromorphone and morphine, Fresenius Kabi said.

“Medication errors due to ‘look-alike’ and ‘sound-alike’ names are real, well documented and can have tragic outcomes for patients,” president & CEO John Ducker said in prepared remarks. “Fresenius Kabi Simplist Dilaudid prefilled syringes can help prevent name confusion between hydromorphone and morphine and to assist health care professionals in delivering the right medication to their patients.”

In December last year, Fresenius Kabi said that it added its heparin sodium injection to the company’s Simplist prefilled syringe portfolio. The prefilled syringe for subcutaneous and intravenous bolus injections expands Fresenius Kabi’s available Heparin formulations.

Earlier that month, the company said it landed a 5-year exclusive distribution deal with Terumo Corp. (TYO:4543) to launch Fresenius’ CATSmart autotransfusion system in the US.

Fresenius said that its CATSmart autotransfusion device, which re-infuses a surgical patient’s own blood, boasts continuous-flow technology, 3 wash programs, an auto-start function and sensors for automatic processing. The companies did not release the terms of the deal, but Terumo Cardiovascular will distribute the devices throughout the U.S.